BeiGene, Ltd., a global oncology leader, has recently made significant strategic moves designed to shape its future. The company has settled litigation securing BRUKINSA patent protection until 2037. As part of its future mission and to reaffirm its focus on oncology, the company has proposed a rebranding to BeOne Medicines. This has lead to a reduction in holdings by Primecap Management Co. CA.
Connor Clark & Lunn Investment Management Ltd and
LMR Partners LLP announced an increase in their investment in the company. Amerities LLC has also increased holdings. BeiGene reported strong revenue growth in Q3 2024, credited largely to BRUKINSA sales surge, and highlighted positive response for TEVIMBRA® as a first-line treatment for advanced cancers. However, the company has been subject to a few controversies, notably a lawsuit by
AbbVie over alleged theft of cancer therapy secrets, and the recent departure of board member Donald Glazer. The company also noted the positive CHMP opinions for TEVIMBRA® and recorded strong growth in spite of facing significant market and financial challenges.
BeiGene, Ltd. News Analytics from Mon, 26 Feb 2024 08:00:00 GMT to Thu, 21 Nov 2024 12:50:00 GMT -
Rating 6
- Innovation 7
- Information 7
- Rumor -3
